Clinical Outcomes of Clareon Vivity Intraocular Lens With Mini-Monovision Approach (NCT05821101) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Clinical Outcomes of Clareon Vivity Intraocular Lens With Mini-Monovision Approach
United States30 participantsStarted 2023-04-06
Plain-language summary
Purpose is to study the clinical outcomes of Clareon Vivity and Clareon Vivity Toric intraocular lens (IOL) implants in patients who are planning to have cataract surgery in both eyes with a mini-monovision approach.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adult patients with bilateral age-related visually significant cataracts in otherwise healthy eyes, undergoing bilateral sequential implantation within 21 days using Clareon Vivity and Clareon Vivity Torics
* IOL powers between +10D to +30.0D, T3-T6
* Potential acuity measured post-operatively 20/25 or better in both eyes
Exclusion Criteria:
* History of ocular or refractive surgery
* Ocular or systemic comorbidities that may alter or reduce visual acuity, contrast sensitivity, binocularity, or impair reading performance such as severe dry eye/ocular surface disease, glaucoma, macular degeneration, retinopathy, neuro-ophthalmic diseases, strabismus/amblyopia etc.
* Patients with irregular astigmatism, corneal dystrophies, pupil abnormalities, zonular laxity
* Intraoperative or postoperative complications
What they're measuring
1
Binocular distance is target-corrected visual acuity (VA) at near 40cm.